|Bid||4.0700 x 900|
|Ask||4.0800 x 1000|
|Day's range||4.0200 - 4.1001|
|52-week range||0.7760 - 7.2500|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
InflaRx N.V. ( NASDAQ:IFRX ) is possibly approaching a major achievement in its business, so we would like to shine...
Regulatory and pipeline updates from Moderna (MRNA) and KALA are the key highlights for the biotech sector.
The biopharmaceutical company's near-term sales outlook has gotten a huge boost following Emergency Use Authorization for one of its drugs.
Shares of InflaRx (NASDAQ: IFRX) were up 48% an hour after the market opened on Wednesday on news the company's COVID-19 therapy was receiving an Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA). The healthcare stock jumped to a 52-week high of $7.25 a share in early trading after the FDA approved an EUA for Gohibic (vilobelimab), a monoclonal anti-human complement factor C5a antibody, to treat hospitalized COVID-19 patients within 48 hours of receiving oxygen through a ventilator or through a heart-lung machine. The EUA is based on the company's successful phase 3 study of the drug on 369 hospitalized patients that showed a 23.9% reduction in the mortality rate compared with placebo.
InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Does InflaRx N.V. (IFRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
InflaRx N.V. (IFRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).